ALTS ALT5 Sigma
- 2.180
- -0.090-3.96%
- 2.220
- +0.040+1.83%
ALT5 Sigma News
Express News | Alt5 Sigma Corp: Tony Issac Will Transition to Role of President While Continuing as Chairman of Board
ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer
ALT 5 Sigma to Exhibit at SiGMA Budapest September 2-4, 2024
ALT5 Sigma Corp Reported Q2 Fintech Revenues Of $2.17M, EPS Of $0.07
ALT5 Sigma Reports Fiscal Financial Results for Second Quarter 2024
10-Q: Q2 2024 Earnings Report
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Express News | ALT5 Sigma Shares Are Trading Higher After the Company Reported a Year-over-year Increase in July Revenue Results
ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024
Express News | ALT5 Sigma Corporation Reports $879M Transaction Volume For Q1 And Q2 2024, A 99% YoY Increase; June 2024 Volume Reaches $124M, Up 68% YoY
ALT5 Sigma Reports 99% Year-Over-Year Increase in Transaction Volume to Over US $879 Million for First Two Quarters of 2024
JanOne Transforms Into ALT5 Sigma With New Ticker Symbol
News On JanOne Inc. (JAN) Now Under ALTS
Express News | Janone Inc - Nasdaq Common Stock Ticker Symbol Will Change to "Alts"
Express News | Janone Confirms Name Change to Alt5 Sigma Corporation and New Ticker Symbol to Alts
JANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTS
Sector Update: Health Care Stocks Advance in Afternoon Trading
Express News | JanOne Board Approves Strategic Review Of Biotech Assets And ALT5 Sigma Being Core Focus Going Forward; Will Change Name To 'ALT5 Sigma Corporation' And Ticker to Change To 'ALTS'
Express News | Janone Inc - Ticker Symbol to Change to Alts
Express News | Janone Inc: Board Has Approved a Strategic Review of Biotech Assets and Alt5 Sigma Being Core Focus Going Forward
Analysis
Price Target
No Data
No Data